CLS Receives Product Order for Laser Ablation Accessories from University Hospital in Germany
Lund, Sweden, 21 April 2020 – Clinical Laserthermia Systems AB (publ) (CLS) today announced that the University Hospital in Magdeburg, Germany has placed a new order for disposable TRANBERG® accessories bringing the total order value from the hospital to SEK 220,000.
The new order is for the, previously announced, ongoing evaluation of the company’s high precision, MR-guided, minimally invasive TRANBERG® Thermal Therapy System for soft tissue treatment of small liver metastases and primary liver tumors. Twelve patients have to date been successfully treated with the MR-guided, Laser interstitial thermal therapy (LITT) procedure without treatment-related side effects.
”In a time when health care institutions all over the world struggle to manage the ongoing pandemia, it is ecourageing that the University Hospital in Magdeburg chose to place an order and plan for continued treatment with our products. It is a positive sign for the future and for our collaboration,” says Lars-Erik Eriksson, CEO of CLS.
The CLS mobile laser unit and disposable products under evaluation by the hospital are managed by CLS’ German subsidiary, CLS GmbH.
Magnetic resonance (MR) -controlled LITT, i.e., laser-induced interstitial thermotherapy is non-invasive, safe and involves directing a laser light, via thin optical fibres, at the tumour in order to destroy it. To ensure that the fibres are optimally placed, imaging techniques such as magnetic resonance or ultrasound are used. LITT-treatment has been confirmed as a safe method that also places a minimal strain on the patient.
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
T: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System including specially designed sterile disposable products for minimally invasive treatment of cancerous tumors, in accordance with regulatory approvals in the EU and in the U.S. The products are marketed for image-guided laser ablation (FLA, LITT) and for treatment with the company’s interstitial laser thermotherapy, imILT®, with a potentially immune stimulating effect. The company, which is headquartered in Lund Sweden and has a subsidiary in Germany and Irvine, CA. is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser (CA) is FNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: info@fnca.se. Further information is available on www.clinicallaser.se.